Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The definition of primary prevention of cardiovascular diseases is presented. Statins preventive value in patients without cardiovascular diseases is analyzed. Randomized controlled studies on primary prevention with statins are briefed. Therapeutic equivalence of statin generics with originator is discussed. 

About the Authors

S. Y. Martsevich
State Research Center for Preventive Medicine, Moscow Medical Academy named after I.M.Setchenov
Russian Federation

Department of preventive pharmacotherapy

Chair of Evidence Based Medicine

Petroverigsky per. 10, Moscow, 101990 

Bolshaya Pirogovskaya ul. 6, Moscow, 119991 

N. P. Kutishenko
State Research Center for Preventive Medicine
Russian Federation

Department of preventive pharmacotherapy

Petroverigsky per. 10, Moscow, 101990 


1. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. М. 1998.

2. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts), Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardio￾vascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414.

3. Kannel W., Dawber T., Friedman G. et al. Risk factors in coronary heart disease: an evaluation of several serum lipids as predictors of coronary heart disease. The Framingham Study. Ann Intern Med 1964;61: 888-99.

4. Hjermann I., Velve Byre K., Holme I., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2(8259):1303-10.

5. Oliver M.E. Cholesterol, coronaries, clofibrate and death. N Engl J Med 1978;299:1360-2.

6. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301-7.

7. Ford I., Murray H., Packard C.J. et al. Long-term follow-up of the West Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86.

8. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.

9. Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or low-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.

10. Colhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.

11. Nakamura H., Arakawa K., Itakura H. et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63.

12. Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.

13. Thavendiranathan P., Bagai A., Brookhart M.A., Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med 2006;166: 2307-13.

14. Brugts J.J., Yetgin T., Hoeks S. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376. doi:10.1136/bmj.2376.

15. The Indian Policap Study (TIPS), Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Policap) on risk factors in middle-aged individuals with￾out cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373(9672):1341-51.

16. Марцевич С.Ю. Проблема лечения статинами в России: помогут ли дженерики? Рациональная Фармакотерапия в Кардиологии 2006;(2):57-60.

17. Аронов Д.М., Бубнова М.Г., Никитин Ю.П. и др. Эффективность и безопасность применения симло (симвастатина) у больных коронарной болезнью сердца с гиперхолестеринемией (результаты многоцентрового клинического исследования). РМЖ 2003;11(19):1088-1092.

18. Марцевич С.Ю., Перова Н.В., Кутишенко Н.П. и др. Открытое клиническое исследование эффективности и безопасности нового дженерика симвастатина – симвастола. Клиническая фармакология и терапия 2005;14(3):55-7.

19. Reiner Ž, Barbič-Žagar B. Efficacy and safety of simvastatin (Vasilip) in high-risk patients with hyperlipidemia and with or without cardio￾vascular disease: the results of a meta-analysis. Liječ Vjesn 2005;127 Suppl 3;62-3.


For citations:

Martsevich S.Y., Kutishenko N.P. PRIMARY PREVENTION OF CARDIOVASCULAR COMPLICATIONS: VALUE OF STATINS. Rational Pharmacotherapy in Cardiology. 2009;5(4):80-84. (In Russ.)

Views: 531

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)